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P
rotease inhibitors have emerged as a powerful drug class.
1
They include the inhibitors of angiotensin converting en-
zyme, inhibitors of HIV proteases, and proteasomal inhibitors
such as Bortezomib (Velcade) used to treat multiple myeloma.
2
The proteases of the endolysosomal pathway have frequently
beenproposedastherapeutictargetsastheyplayimportantroles
in the regulation of a wide variety of biological systems.
3 For
example, lysosomal cysteine and aspartyl proteases are validated
drug targets in several trypanosome species,
4 and the upregula-
tion of certain endosomal proteases is associated with increased
malignancy.
5 Asparagine endopeptidase (AEP or legumain) has
alsobeenimplicatedintheprogressionofmalignant melanoma,
6
in the destruction of the therapeutic drug L-asparaginase,
7 and
in neuroexitotoxity.
8 Down-regulation of cystatins, which are
natural cysteine protease inhibitors, can lead to increased
malignancy
9 and faulty immune responses.
10 High expression
of cathepsin D (Cat D) in non-Hodgkin’s lymphoma has also
been associated with increased malignancy
11 and is also asso-
ciated with poor prognosis in breast cancer.
12 A further potential
therapeutic application of endosomal protease inhibitors would
be immune modulation since several recent studies demonstrate
that the proteolytic activity in endosomes of antigen presenting
cells may be too high, leading to antigen destruction and
ineﬃcient presentation to T-cells. Consequently, protease-resis-
tant antigens often elicit more robust immune responses.
13,14
Taken together, it seems that eﬀective down-modulators of
endo/lysosomal protease activity could be a valuable addition to
the therapeutic armory. However, to date modulation of endo/
lysosomal protease function has remained challenging, as there
are multiple families of endosomal proteases with an extensive
functional redundancy.
15 As an additional problem, there is
evidence in the literature that the knock-down/inhibition of
speciﬁc proteases leads to the upregulation of others.
3,16,17
Mostendosomalproteasesbelongto3distinctfamilies.There
are several papain-like cysteine proteases (PLCPs), including
cathepsin L, S, B, C as well as several others.
18 Alongside these
there are the aspartyl proteases related to pepsin: cathepsins D
and E. Finally, there is an additional cysteine protease termed
asparaginylendopeptidase(AEP)orlegumainthatismoreclosely
related to the caspases.
19 Each of these 3 classes can be inhibited
bydistinctandnonoverlappingsmallmoleculeinhibitors,
20,21but
in vivo inhibition, or knockout, of these proteases frequently
shows limited or no phenotype, most likely due to functional
redundancy. We thus postulated that inhibiting all three families of
endosomalproteaseswouldprovideapowerfultoolfor modulating
endo/lysosomal function.
PLCPsandAEParepotentlyinhibitedbyanaturallyoccurring
14 kDa protein, cystatin C. The cystatins are a family of small
proteins that inhibit PLCPs with subnanomolar aﬃnity.
22 They
are present in the bloodstream and are believed to play a role in
the mopping up of proteases released during physiological and
pathological responses.Importantly,cystatinC,as wellasseveral
family members, inhibit AEP via a distinct binding site with a Ki
of 0.20 nM
23 (Figure 1). Cystatin C thus represents an excellent
scaﬀold for the synthesis of a pan-endosomal protease inhibitor.
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ABSTRACT: Proteasesconstitute amajor classof drug targets.
Endosomal compartments harbor several protease families
whose attenuation may be beneﬁcial to a number of biological
processes, including inﬂammation, cancer metastasis, antigen
presentation,andparasiteclearance.Asasteptowardthegoalof
generalized but targeted protease inhibition in the endocytic
pathway, we describe here the synthesis, characterization, and
cellularapplicationofanovelmultifunctionalproteaseinhibitor.
We show that pepstatin A, a potent but virtually insoluble
inhibitor of cathepsins D and E, can be conjugated to a single
site on cystatin C, a potent inhibitor of the papain-like cysteine
proteases(PLCP)andofasparagineendopeptidease(AEP),tocreateahighlysolublecompoundcapableofsuppressingtheactivity
ofall3principalproteasefamiliesfoundinendosomesandlysosomes.Wedemonstratethatthiscystatinpepstatininhibitor(CPI)
can be taken up by cells to modulate protease activity and aﬀect biological responses.1199 dx.doi.org/10.1021/cb200292c |ACS Chem. Biol. 2011, 6, 1198–1204
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Cathepsin D and E, the endosomal aspartyl proteases, are
inhibited with a Ki of 0.1 nM by pepstatin A,
24 an isopeptide ﬁrst
isolated from Actinomyces. Its major drawback is its virtual
insolubility in aqueous media.
24 Nonetheless it is still widely used
evenincell-basedassays becausemoresolublealternativesare not
readily available. Several attempts have been made to address this
problem, such as conjugating pepstatin A to asialoglycoprotein-
(ASGP)
25 or to poly(ethylene glycol)
26 or more recently by
mannosylating it, or conjugatingittomannosylated bovine serum
albumin.
27,28 PEG-ylation of pepstatin reduces its inhibitory
potential 400-fold, and conjugating to mannosylated BSA reduces
the Ki 10-fold, whereas conjugation to ASGP renders pepstatin
inactive until the protein backbone is digested. Conjugation of
pepstatin to peptides or ﬂuorescent moieties did not signiﬁcantly
alter its inhibitory potential.
29,30
In a novel approach, we decided to use cystatin C as the
solubilizing agent for pepstatin A via a reducible peptide spacer
linkage, thereby creating a highly soluble “Swiss army knife”
protease inhibitor (ﬁgure 1) capable of suppressing the activity
of all 3 major protease families that populate endosomes and
lysosomes and that control their biological functions.
31
’RESULTS AND DISCUSSION
We wanted tight control over the stoichiometry and localiza-
tionoftheintroducedpepstatin,withnomorethanonepepstatin
molecule per cystatin at a site away from the inhibitory domains
of cystatin C (see Supplementary Figure S1a), and thus intro-
duced a free cysteine into the protein backbone by site-directed
mutagenesis,
32,33 as itcan beselectively modiﬁedinthe presence
of other nucleophilic residues. Issues associated with disulﬁde
scrambling with the two existing disulﬁde bridges in cystatin C
were avoided by using a mammalian expression system. Various
mutants were tested (see Supplementary Figure 1ac), and
T102C was found to have the most favorable inhibitory proper-
ties. A C-terminal 6His-tag was also introduced, for puriﬁcation
and possible conjugation of the inhibitor to a solid phase carrier.
Figure 1. Modeling of a cystatinpepstatin inhibitor conjugate (CPI)
as a potential inhibitor of all 3 major endosomal protease families: the
papain-like cysteine proteases (PLCP), aspartyl proteases (Cat-D/E),
and asparagine endopeptidase (AEP) are inhibited through 3 diﬀerent
motifs on the construct.
Figure 2. Conjugation of pepstatin A to cystatin C T102C through a solubilizing peptide carrying a C-terminal MTS-cysteine residue. Conditions:
(i) EDC/HOSu in DMF 96% yield; (ii) Fmoc-lysine/DMF, 89% yield; (iii) Fmoc-based solid phase peptide synthesis; (iv) PBS with 6% v/v DMSO,
>90% conversion, 95% protein recovery.1200 dx.doi.org/10.1021/cb200292c |ACS Chem. Biol. 2011, 6, 1198–1204
ACS Chemical Biology ARTICLES
Wechosetousemethanethiosulfonatechemistrytointroduce
the pepstatin onto the free cysteine of cystatin C,
33,34 due to its
high selectivity for sulfhydryls and its facile introduction into the
peptide backbone through a MTS-Boc-cysteine building block.
Furthermore there is the potential for endosomal release of the
pepstatinmoietybyreductionofdisulﬁdesbythelysosomalthiol
reductase GILT.
35
Initial eﬀorts focusing on an analogue with an ethyl spacer
between pepstatin and the MTS moiety resulted in <5% protein
recovery due to poor solubility of the resulting conjugate. As it
has been reported that conjugation of the C-terminal end of
pepstatintolysineresiduesdidnotreduceitsinhibitorypotential
signiﬁcantly,
29,30 we decided to introduce a charged peptide
betweenthepepstatinandtheMTSgroup(Figure 2)toincrease
solubility of the conjugate. It was found that a mild reduction
(5 mM DTT) was needed prior to the modiﬁcation reaction as
thefreecysteinehadbecomemodiﬁedduringtheexpressionand
puriﬁcation process (Supplementary Figure S2). This improved
protein recovery levels to >95% with >90% modiﬁcation as
determined by mass spectrometry and SDS-PAGE analysis
(Figure 2 and Supporting Information).
Next, we used ﬂuorescent substrates that are cleaved speciﬁ-
cally by members of each of the three families of proteases to
analyze the inhibitory capacity of our cystatinpepstatin inhi-
bitor(CPI;Figure3a,b).WhenlookingatthepotentialofCPIto
inhibit recombinant enzymes, we found it inhibited the PLCP
cathepsin L, AEP, and cathepsin D with a similar IC50 as wt-
cystatin C and pepstatin A. Moreover, the CPI was also able to
inhibit the 3 classes of protease activity present in dendritic
cell lysates (Figure 3b). When the CPI conjugate was incu-
bated with live mouse dendritic cells and their protease
activity was determined postlysis, we found that the probe
could simultaneously abolish cathepsin D/E activity aswellas
reduce PLCP and AEP activity by >90% (Supplementary
Figure S3) with no cell death occurring (as determined by
trypan blue assay).
Figure 3. (a) Residual protease activity in ﬂuorescence units per minute of recombinant cathepsin L, AEP, and cathepsin D in the presence of varying
concentrations of CPI, cystatin, or pepstatin as measured using ﬂuorescent substrates speciﬁc for each protease. (b) Residual activity of the same
enzymesasmeasuredinlysatesderivedfromdendriticcellsusingthesameﬂuorescentsubstratesasinpanela.NotethatonlyCPIinhibitsall3protease
activities. (c) Fluorescence microscopy of quenched casein substrate (Enzcheck). Upon hydrolysis, the Enzcheck ﬂuorophore is dequenched and emits
green ﬂuorescence, indicating protease activity. A20 antigen-presenting cells (APCs) were incubated with the Enzcheck substrate and treated in the
absence or presence of CPI, cystatin, or pepstatin. Representative images of ﬁxed cells immuno-stained for the late endosomal marker CD63 (red) are
shown(scalebar,10μm).(d)QuantiﬁcationofinitialratesofEnzcheckﬂuorescenceemergenceinliveA20cellsasmeasuredonanEnvisionﬂuorimeter.
Quenched Bodipy-casein (Enzcheck) was incubated with A20 cells in the presence or absence of CPI, cystatin C. Error bars represent SD based on a
representative experiment performed in triplicate.1201 dx.doi.org/10.1021/cb200292c |ACS Chem. Biol. 2011, 6, 1198–1204
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We next wanted to visualize the protease inhibition in live
cells, rather than postlysis. For this we used a heavily BODIPY
dye labeled casein construct (Enzcheck substrate). The high
density of BODIPY groups results in the ﬂuorescence being
quenched. Upon proteolysis, however, the degradation of the
protein backbone results in the dequenching of the BODIPY
groups,resultingintheemergenceofﬂuorescence.
36Firstwehad
to demonstrate that this substrate was susceptible to cleavage by
all three families of proteases, as some proteins are only cleaved
(in vitro at least) byspeciﬁcprotease families.
14,15 To test this we
incubated the quenched ﬂuorophore with mouse macrophage
lysosomes,whichareknowntoberichinproteasesfromallthree
families. Indeed it was observed that the substrate was stabilized
more eﬀectively by CPI, relative to a PBS-control, than it was by
cystatin C and pepstatin A alone (Supplementary Figure S4).
For the live cell assays we used the murine antigen presenting
cell line A20, since it is resistant to relatively high levels of
unconjugated pepstatin A needed for these experiments, which
on the time scale for this experiment would be toxic to primary
dendritic cell cultures.
37 It also possesses high levels of all three
families of proteases. When the cells were treated with PBS, we
observedthedequenchingofthesubstratebyconfocalmicroscopy
(Figure 3c) in approximately 8% of all cells after 5 h. Longer
timecourses resulted in extensive cell death in pepstatin-treated
samples. When the component inhibitor inhibitor cystatin C or
pepstatinAwasadded,thisnumberwasreducedtoapproximately
4%.WhenCPIwasaddedtogetherwiththequenchedcasein<1%
of cells became ﬂuorescent. Proteolytic processing of BODIPY-
casein could thus be stopped by the addition of the CPI. We also
conﬁrmed this observation by measuring the emergence of
BODIPY ﬂuorescence by ﬂuorimetry. When A20 cells were
incubated with or without the inhibitors and BODIPY ﬂuores-
cence was measured at a the 5 h time point (Figure 3d), it was
again observed that the BODIPY casein was dequenched more
slowly in the presence of the CPI than it was in the presence of
cystatin C or pepstatin A alone.
One of the potential therapeutic applications of the CPI is as a
modulator of antigen processing. It has been reported that that
protease-resistant antigens can make better immunogens and that
reducing levels of proteases can boost antigen presentation. For
example,inarecentstudybyDelamarreetal.
13itwasdemonstrated
that a heme-free form of horseradish peroxidase (apo-HRP) was
more sensitive to lysosomal proteolysis than wild-type, heme-
containing HRP (wt-HRP) in vitro. In vivo,a p o - H R Pi n d u c e d
muchweakerimmuneresponsesthanwt-HRP,leadingtheauthors
to suggest that apo-HRP was degraded too rapidly by the antigen
processing machinery, preventing eﬃcient loading of MHC com-
plexes. We asked whether we could protect unstable apo-HRP
fromlysosomaldegradationinvitroby adding the CPI. As a source
ofendolysosomalproteasesweagainusedpuriﬁedlysosomesfrom
mouse macrophages. Indeed, after a 6 h incubation, apo-HRP was
completely degraded (Figure 4a). In fact, more than 90% of the
proteinwasdegradedevenaftera1hincubation(datanotshown).
In contrast, a substantial fraction of wt-HRP remained intact after
6h.AdditionofcystatinCorpepstatinAindividuallyproducedonly
modest stabilization of apo-HRP (Figure 4a; left, lanes 3 and 5),
indicating a functional redundancy between the lysosomal en-
zymesinthesemacrophages.However,additionofCPIstabilized
apo-HRP dramatically such that after 6 h the amount remaining
wassimilartowt-HRPdigestedintheabsenceofCPI(Figure4a;
left, lane 4). These results suggest that incorporation of CPI into
immunological adjuvants for unstable antigens may be worth-
while and is currently under investigation.
WenextassessedthecapacityofCPItoinhibitendo/lysosomal
proteasesinlivecellsandwhetheritcouldmodulatethebiological
functionsofthiscompartmentalsystem.Oneimportantroleofthe
Figure4. (a)Protectionofadestabilized variantofHRP(apo-HRP)andstablewild-typeHRP(wt-HRP)fromdegradationbymacrophagelysosomes
(6hincubationat37C;pH4.5).Inhibitorsaddedasindicatedataﬁnalconcentrationof5μM.OnlyCPIprotectstheunstablevariantapo-HRP(lane4).
Cystatin C (lane 3) and pepstatin A (lane 5) oﬀer only partial protection against degradation of this destabilized protein. wt-HRP is largely stable in the
presence of macrophage lysosomes (lanes 711). (b) CPI arrests EGF receptor downregulation and sustains signaling. COS7 cells were stimulated with
EGF for up to 90 min following a preincubation in the presence or absence of CPI or cystatin C (15 μM ﬁnal concentration). The downregulation of the
EGF receptor (top panel) was assayed by Western blotting along with levels of phospho-Erk1/2 (p42/44 MAP kinase; bottom panel) and Rsk2 to assess
total cellular protein loading (middle panel). (c) EGFR abundance throughout the treatment time course relative to t = 0 (left panel); phosphorylated
p42/44 abundance throughout the treatment time course relative to t = 20 min (right panel).1202 dx.doi.org/10.1021/cb200292c |ACS Chem. Biol. 2011, 6, 1198–1204
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endocytic pathway is to degrade activated growth factor receptors
following their ligand-stimulated endocytosis. For example, fol-
lowing ligand stimulation, the EGF receptor (EGFR) is ubiquiti-
nated, clustered in clathrin coated pits, and delivered to the
endosome system where it becomes sequestered on the internal
vesiclesofmultivesicularbodies(MVBs)preventingrecyclingand
shutting down its capacity to signal.
3840 MVBs then fuse with
lysososomes, and the EGF receptor is degraded, although the
speciﬁc lysosomal proteases that degrade EGF receptor remain to
be fully deﬁned, with the cysteine proteases all implicated.
11
WepreincubatedtheEGFR-positivekidneycelllineCOS-7in
the presence or absence of CPI or cystatin C (the insolubility of
pepstatin A prevented this compound from giving meaningful data
in this experiment) and then challenged with EGF. At diﬀerent
times following treatment the total cellular levels of EGFR remain-
ing were monitored by Western blotting (Figure 4b). In control
cellsdownregulationofEGFRwasevidentafter40minandvirtually
complete after 90 min. By contrast, EGFR levels persisted in cells
preincubated with CPI, demonstrating a block in receptor degrada-
tion (Figure 4c; left panel). Preincubation with cystatin C also
suppressed EGFR downregulation, but not to the same extent as
CPI, indicating that both cysteine and aspartyl proteases are
involved in EGFR processing. The arrest in receptor degradation
wasnotduetoinhibitortoxicitysincetheMAPkinasesErk1/2were
activatednormallyinCPIandcystatinCtreatedcells(Figure4b).In
fact, sustained Erk activation was seen in the presence of CPI
(Figure 4c; right panel), consistent with the prolonged half-life of
EGFR observed in the same samples (left panel).
Perturbationsintheproteolyticcapacityofendosomesmaynot
only impinge on protein turnover within but also aﬀect progres-
sion of material along the endocytic subcompartments. To assess
the eﬀect(s) of CPI on endocytosis of cell surface receptors, we
examined ligand-mediated traﬃcking of EGFR. HeLa cells ex-
pressing high endogenous levels of EGFR were pretreated in the
presence or absence of CPI and stimulated with EGF for 5 and
90 min to allow observation of early and late events in receptor
endocytosis, respectively (Figure 5). Following treatment, sam-
ples were ﬁxed and immunostained for EGFR (green) and the
transferrin receptor (TrfR, red). TrfR, also abundant in HeLa
cells, is known to constitutively endocytose and recycle
41 but
unlike EGFR does not travel downstream to the proteolytic late
endosomes. It is therefore commonly used as a marker of early
endosomes. As observed by confocal immuno-ﬂuorescence
microscopy, disappearance of EGFR following ligand treatment
was substantially reduced in the presence of CPI relative to the
control (Figure 5a, bottom panels), while the initial levels of
internalized receptor appeared comparable (top panels). As stability
of TrfR is unaﬀected by EGF stimulation, EGFR abundance in this
assay was quantiﬁed relative to that of TrfR in the same cells
(Figure 5b). These data further substantiate the CPI-dependent
attenuationofEGFRturnover inthe Westernblotassay(Figure4b),
asthepresenceofEGFRonearlyendosomesandadequateinduction
of signaling shortly following ligand addition rule out the possibility
thatpreincubationwithCPIinterfereswithreceptorinternalizationor
alternatively abolishes receptor access to the plasma membrane.
Persistent localization of transitory membrane cargo to TrfR-
positive endosomes can be associated with blocked traﬃcking of
EGFR toward the lysosome.
42 Importantly, nearly half of the
EGFR remaining in the presence of inhibitor at 90 min after
stimulation with EGF still colocalized with TrfR, an extent similar
tothatobservedatthe5mintime-pointundereitherpretreatment
condition (Figure 5a, bottom panel; Figure 5c). By contrast, in
control cells only a small fraction of residual EGFR was found on
TrfR-positive endosomes at this late time-point. Taken together
with the Western blot data, these results allow us to tentatively
hypothesizethatCPIretardsthematurationoftheEGFR-positive
endosomes,therebyaﬀordingprolongedligand-inducedsignaling.
In summary, we have presented the construction of a single
molecular entity that inhibits all three major families of endo/
lysosomal proteases. This broad inhibition has been shown to
attenuate destructive processing of labile proteins in vitro and to
attenuate proteolytic events within the endo/lysosomal pathway
in vivo. CPI and variants of it may be therapeutically useful not
only because of its broad inhibitory range but because it can be
readily modiﬁed to permit targeting to speciﬁc cell types, thus
avoiding toxicity associated with systemically administered small
molecular protease inhibitors. Moreover, the spectrum of lyso-
somal cysteine proteases targeted can be manipulated through
mutation of the PLCP and AEP interacting domains.
23,43
’METHODS
SynthesisoftheCystatinPepstatin Conjugate(3). Dithio-
threitol (DTT) was added to a solution of cystatin C-T102C-6His
Figure 5. Confocal images of EGFR degradation. Inhibition of endo-
lysosomal proteases slows EGFR downregulation and alters receptor
traﬃcking. (a) Immunoﬂuorescence microscopy of HeLa cells preincu-
b a t e di nt h ep r e s e n c eo ra b s e n c eo fC P Ia n ds t i m u l a t e dw i t hE G Fa s
indicated. Fixed samples were immunostained against endogenous EGFR
(leftpanels,green) and transferrinreceptor(TrfR,middlepanels,red) with
merges of the two channels shown (right panels). Representative images
taken under the same magniﬁcation and laser settings are shown with 6x
inset magniﬁcation and scalebar corresponding to 10 μm. (b) Quantiﬁca-
tion of EGFR abundance expressed as a fraction of TrfR in the same cells is
r e p r e s e n t e dr e l a t i v et on oi n h i b i t o r ,t=5minsample. (c) Quantiﬁcation of
colocalization between the two receptors expressed as a fraction of EGFR
overlappingTrfR.Errorbars forquantiﬁcationcorrespondto SDcalculated
on the basis of 2025 cells for each conditions using Student’s t test.1203 dx.doi.org/10.1021/cb200292c |ACS Chem. Biol. 2011, 6, 1198–1204
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(1mgmL
1inPBS,2.5mL) toafinalconcentrationof5mM.Themixture
was gently shaken at RT for 10 min and buffer exchanged into phosphate
buffered saline (PBS) by Sephadex G-25 resin (GE Healthcare). The
reduced protein (50 μM 3.5 mL) was added to a solution of 2 in DMSO
(2 mM, 200 μL), and the mixture was gently shaken at RT for 2 h, after
which SDS-PAGE and LCMS analysis showed the formation of a
single product. The protein was purified after modification using nickel
affinity chromatography, followed by dialysis into PBS (60008000
MWCO, 3  4L ) .
’ASSOCIATED CONTENT
b S Supporting Information. Characterization of cystatin C
mutants, synthesis of the pepstatin analogue, optimization of the
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procedures. This material is available free of charge via the
Internet at http://pubs.acs.org.
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